Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 14/20 | 0.50 |
| ▸ | KDR | P35968 | 5/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | BCL6 | P41182 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16363363 | 0.77 | TNNI3K (0.58) | TNNI3KEGFRKDRPOLBMAPT | |
| SCHEMBL6216117 | 0.75 | EGFR (0.49) | EGFRKDRERBB2GRM1AURKA | |
| SCHEMBL21617837 | 0.75 | TNNI3K (0.39) | TNNI3KEGFRKDRERBB2POLB | |
| SCHEMBL6214917 | 0.74 | PIP4K2A (0.51) | EGFRKDRERBB2FGFR1GRM1 | |
| SCHEMBL3398349 | 0.74 | TTBK1 (0.52) | TNNI3K | |
| SCHEMBL22303729 | 0.72 | SRC (0.41) | TNNI3KEGFRKDRFGFR1FLT4 | |
| SCHEMBL21620789 | 0.72 | TNNI3K (0.40) | TNNI3KEGFRKDRERBB2FGFR1 | |
| SCHEMBL21620593 | 0.72 | TNNI3K (0.38) | TNNI3KEGFRKDRERBB2PDGFRB | |
| SCHEMBL21617773 | 0.72 | TNNI3K (0.40) | TNNI3KEGFRKDRERBB2FGFR1 | |
| SCHEMBL21620792 | 0.72 | TNNI3K (0.38) | TNNI3KEGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697692-B2 | Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2014-04-15 | — | — | US | disclosed |
| EP-1973910-B1 | PYRROLO[3,2-C]PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2013-06-26 | — | — | EP | disclosed |
| US-8362251-B2 | Pyrrolo [3,2-C] pyridine-4-one 2-indolinone protein kinase inhibitors | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-01-29 | — | — | US | disclosed |
| US-20120058107-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-03-08 | — | — | US | disclosed |
| US-20110301353-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2011-12-08 | — | — | US | disclosed |
| US-8012966-B2 | Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2011-09-06 | — | — | US | disclosed |
| US-20100004239-A1 | Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2010-01-07 | — | — | US | disclosed |
| EP-1973910-A1 | PYRROLO Ý3,2-C¨PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007085188-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2007-08-02 | — | — | WO | disclosed |
| EP-1259514-B9 | 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS | SUGEN INC (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1244672-B1 | 4-SUBSTITUTED 7-AZA-INDOLIN-2-ONES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2005-07-20 | — | — | EP | disclosed |
| US-6908930-B2 | 4-substituted 7-AZA-indolin-2-ones and their use as protein kinase inhibitors | SUGEN, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| EP-1259514-B1 | 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS | SUGEN INC (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040053924-A1 | 4-Substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | SUGEN, INC. | 2004-03-18 | — | — | US | disclosed |
| US-6610688-B2 | For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer | SUGEN, INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020183319-A1 | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | SUGEN, INC. | 2002-12-05 | — | — | US | disclosed |
| US-6465507-B2 | ANTITUMOR AGENTS | SUGEN, INC. | 2002-10-15 | — | — | US | disclosed |
| EP-1244672-A1 | 4-SUBSTITUTED 7-AZA-INDOLIN-2-ONES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020042427-A1 | 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors | SUGEN, INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2001046196-A1 | 4-SUBSTITUTED 7-AZA-INDOLIN-2-ONES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058107-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | DMPK, PDPK1, PRKAR2A | TNNI3K 50/4885EGFR 791/4885KDR 1027/4885 |
| US-20110301353-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | DMPK, PDPK1, PRKAR2A | TNNI3K 50/4885EGFR 791/4885KDR 1027/4885 |
| US-20040053924-A1 | 4-Substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | CDKN1A, CSNK1A1, CDK2 | TNNI3K 141/4885EGFR 295/4885KDR 1406/4885 |
| US-20020183319-A1 | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors | CDKN1A, CDK7, CDK2 | TNNI3K 242/4885EGFR 100/4885KDR 1026/4885 |
| US-20100004239-A1 | Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors | DMPK, CDK2, PRKAR2A | TNNI3K 50/4885EGFR 799/4885KDR 780/4885 |
| US-20020042427-A1 | 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors | MAP3K20, MAP3K6, MAP3K3 | TNNI3K 18/4885EGFR 684/4885KDR 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.